Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Role of network branching in eliciting differential short-term signaling responses in the hypersensitive epidermal growth factor receptor mutants implicated in lung cancer.

Purvis J, Ilango V, Radhakrishnan R.

Biotechnol Prog. 2008 May-Jun;24(3):540-53. doi: 10.1021/bp070405o. Epub 2008 Apr 16.

PMID:
18412405
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.

Tabara K, Kanda R, Sonoda K, Kubo T, Murakami Y, Kawahara A, Azuma K, Abe H, Kage M, Yoshinaga A, Tahira T, Hayashi K, Arao T, Nishio K, Rosell R, Kuwano M, Ono M.

PLoS One. 2012;7(7):e41017. doi: 10.1371/journal.pone.0041017. Epub 2012 Jul 17.

PMID:
22815900
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

A multiscale computational approach to dissect early events in the Erb family receptor mediated activation, differential signaling, and relevance to oncogenic transformations.

Liu Y, Purvis J, Shih A, Weinstein J, Agrawal N, Radhakrishnan R.

Ann Biomed Eng. 2007 Jun;35(6):1012-25. Epub 2007 Feb 2.

PMID:
17273938
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

[Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].

Han R, Wang X, Zhong D, Zhao J, Chen Z, Sun L, Wang J, Zhang J.

Zhongguo Fei Ai Za Zhi. 2012 Dec;15(12):689-93. doi: 10.3779/j.issn.1009-3419.2012.12.02. Chinese.

PMID:
23249714
[PubMed - indexed for MEDLINE]
Free Article
5.

Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene.

Li T, Ling YH, Perez-Soler R.

J Thorac Oncol. 2008 Jun;3(6):643-7. doi: 10.1097/JTO.0b013e3181753b24.

PMID:
18520805
[PubMed - indexed for MEDLINE]
6.

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.

PMID:
15289342
[PubMed - indexed for MEDLINE]
Free Article
7.

Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC.

Patel MR, Jay-Dixon J, Sadiq AA, Jacobson BA, Kratzke RA.

J Thorac Oncol. 2013 Sep;8(9):1142-7. doi: 10.1097/JTO.0b013e31829ce963.

PMID:
23883783
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.

Wang M, Zhao J, Zhang LM, Li H, Yu JP, Ren XB, Wang CL.

J Cancer Res Clin Oncol. 2012 Dec;138(12):2069-77. doi: 10.1007/s00432-012-1291-2. Epub 2012 Jul 22.

PMID:
22821179
[PubMed - indexed for MEDLINE]
9.

Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation.

Uchida A, Hirano S, Kitao H, Ogino A, Rai K, Toyooka S, Takigawa N, Tabata M, Takata M, Kiura K, Tanimoto M.

Cancer Sci. 2007 Mar;98(3):357-63.

PMID:
17270025
[PubMed - indexed for MEDLINE]
10.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

PMID:
22457323
[PubMed - indexed for MEDLINE]
Free Article
11.

Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.

Lange F, Rateitschak K, Kossow C, Wolkenhauer O, Jaster R.

World J Gastroenterol. 2012 Nov 21;18(43):6226-34. doi: 10.3748/wjg.v18.i43.6226.

PMID:
23180942
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells.

Serizawa M, Murakami H, Watanabe M, Takahashi T, Yamamoto N, Koh Y.

Cancer Sci. 2014 Jun;105(6):683-9. doi: 10.1111/cas.12411. Epub 2014 May 10.

PMID:
24698130
[PubMed - indexed for MEDLINE]
13.

Cigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors.

Filosto S, Becker CR, Goldkorn T.

Mol Cancer Ther. 2012 Apr;11(4):795-804. doi: 10.1158/1535-7163.MCT-11-0698. Epub 2012 Feb 1.

PMID:
22302097
[PubMed - indexed for MEDLINE]
Free Article
14.

RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib.

Xu ZH, Hang JB, Hu JA, Gao BL.

Int J Clin Exp Pathol. 2013 Jul 15;6(8):1493-504. Print 2013.

PMID:
23923067
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.

N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29.

PMID:
15118073
[PubMed - indexed for MEDLINE]
Free Article
16.

Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.

Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA Jr.

Clin Cancer Res. 2006 Dec 1;12(23):7117-25.

PMID:
17145836
[PubMed - indexed for MEDLINE]
Free Article
17.

Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.

Takata M, Chikumi H, Miyake N, Adachi K, Kanamori Y, Yamasaki A, Igishi T, Burioka N, Nanba E, Shimizu E.

Cancer Biol Ther. 2012 Apr;13(6):369-78. doi: 10.4161/cbt.19238. Epub 2012 Apr 1.

PMID:
22313637
[PubMed - indexed for MEDLINE]
19.

Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type.

VanMeter AJ, Rodriguez AS, Bowman ED, Jen J, Harris CC, Deng J, Calvert VS, Silvestri A, Fredolini C, Chandhoke V, Petricoin EF 3rd, Liotta LA, Espina V.

Mol Cell Proteomics. 2008 Oct;7(10):1902-24. doi: 10.1074/mcp.M800204-MCP200. Epub 2008 Aug 6.

PMID:
18687633
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.

Suda K, Mizuuchi H, Sato K, Takemoto T, Iwasaki T, Mitsudomi T.

Int J Cancer. 2014 Aug 15;135(4):1002-6. doi: 10.1002/ijc.28737. Epub 2014 Feb 4.

PMID:
24458568
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk